Volume 27, Number 11—November 2021
Research
Genomic Profiling of Mycobacterium tuberculosis Strains, Myanmar
Table 2
Drug | Performance of genome-based† drug resistance profile prediction with respect to phenotypic drug-susceptibility testing |
||||||
---|---|---|---|---|---|---|---|
Mutation |
No mutation |
Sensitivity, % | Specificity, % | ||||
Sensitive | Resistant | Sensitive | Resistant | ||||
Isonizaid | 0 | 196 | 113 | 0 | 100.0 | 100.0 | |
Rifampin | 0 | 191 | 118 | 0 | 100.0 | 100.0 | |
Ethambutol | 34 | 80 | 155 | 40 | 70.2 | 79.5 | |
Streptomycin | 26 | 140 | 80 | 63 | 84.3 | 55.9 | |
Ofloxacin/levofloxacin/capreomycin | 13 | 31 | 263 | 2 | 70.4 | 99.2 | |
Amikacin/kanamycin | 0 | 6 | 303 | 0 | 100.0 | 100.0 | |
Para-aminosalicylic acid | 15 | 0 | 294 | 0 | NA | 100.0 | |
Ethionamide | 4 | 28 | 274 | 3 | 87.5 | 98.9 | |
D-cycloserine | 0 | 0 | 309 | 0 | NA | 100.0 |
*NA, not applicable. †Whole-genome sequencing‒based prediction.
1These authors contributed equally to this article.
Page created: July 13, 2021
Page updated: October 19, 2021
Page reviewed: October 19, 2021
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.